ARCHIVES

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Senate Outlines Budget Priorities In Bill Report

July 19, 1991

NCAB Oks Organ Systems Plan, Criteria For Starting, Ending Working Groups

October 7, 1988

Interview: Von Eschenbach Says His Goal Is to Speed Development of Interventions

March 29, 2002

In Brief: Senate Subcommittee Vote: $950 Million Plus training DeVita Needs New Clinical Assistant

July 21, 1978

NCAB Supports NCI Director’s Call For Increase In Management Funds.

December 8, 2000